Santero Therapeutics

Executive Summary

Santero Therapeutics is a Belgian biotechnology company founded in 2021, headquartered in Leuven, that is pioneering first-in-class treatments for chronic, treatment-refractory bacterial infections. Unlike traditional approaches that target antibiotic resistance, Santero focuses on bacterial persistence—a state where bacteria become dormant and tolerant to antibiotics. The company's platform targets conserved bacterial enzymes, enabling either direct killing of dormant bacteria or resensitizing them to existing antibiotics. This innovative strategy addresses a critical unmet need in infectious disease, where persistent infections contribute to high morbidity and healthcare costs. Although still in early stages with no disclosed funding rounds or pipeline details, Santero's unique scientific premise positions it as a potential game-changer in the fight against chronic infections. The company's progress will depend on advancing its platform through preclinical validation and securing partnerships or financing to move toward clinical development.

Upcoming Catalysts (preview)

• H2 2026Series A Financing Announcement60% success
• Q4 2026Preclinical Proof-of-Concept Data Release50% success
• H1 2027Academic or Industry Partnership40% success